key: cord-1043299-1n8im478
authors: Robbins-Juarez, Shelief Y.; Qian, Long; King, Kristen L.; Stevens, Jacob S.; Husain, S. Ali; Radhakrishnan, Jai; Mohan, Sumit
title: A Systematic Review and Meta-Analysis Of Outcomes for Patients with COVID-19 and Acute Kidney Injury
date: 2020-06-25
journal: Kidney Int Rep
DOI: 10.1016/j.ekir.2020.06.013
sha: e4e887a1e7960bbe0535febbdc264bd92be2050c
doc_id: 1043299
cord_uid: 1n8im478

INTRODUCTION: There is limited data on the association of kidney dysfunction with prognosis in COVID-19, and the extent to which acute kidney injury (AKI) predisposes patients to severe illness and inferior outcomes is unclear. We aim to assess the incidence of AKI among patients with COVID-19 and examine their associations with patient outcomes as reported in the available literature thus far. METHODS: We systematically searched MEDLINE, EMBASE, SCOPUS, and MedRxiv databases for full-text articles available in English published from December 1, 2019 to May 24, 2020. Clinical information was extracted and examined from 20 cohorts that met inclusion criteria, covering 13137 mostly hospitalized patients confirmed to have COVID-19. Two authors independently extracted study characteristics, results, outcomes, study-level risk of bias, and strength of evidence across studies. Neither reviewer was blind to journal titles, study authors, or institutions. RESULTS: Median age was 56 years, with 55% male patients. Approximately 43% of patients had severe COVID-19 infection, and approximately 11% died. Prevalence of AKI was 17%; 77% of patients with AKI experienced severe COVID-19 infection, and 52% died. AKI was associated with increased odds of death among COVID-19 patients (pooled odds ratio 15.27, 95% CI 4.82-48.36), although there was considerable heterogeneity across studies and among different regions in the world. Approximately 5% of all patients required use of renal replacement therapy (RRT) CONCLUSIONS: Kidney dysfunction is common among patients with COVID-19, and patients who develop AKI have inferior outcomes. Additional research into management and potential mechanisms of this association is needed.

• Overall Mortality 11%

• AKI 17%

• AKI + Severe / ICU 77%

• AKI + Death 52%

• Total RRT 5.0%

• pOR AKI + Death 15.27 (95% CI 4.82-48.38)

Kidney dysfunction is common among patients with COVID-19, and patients who develop AKI have inferior outcomes. Additional research into management and potential mechanism of this association is needed. Following the emergence of a cluster of infections causing respiratory failure in Wuhan, Hubei

Province, China in December 2019, researchers identified severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) as the causative pathogen for the respiratory disease later named COVID-19 by the World Health Organization. 1 Morbidity and mortality from COVID-19 have been primarily attributed to respiratory failure and acute respiratory distress syndrome (ARDS), often in the setting of multi-organ failure. 2, 3, 4 The incidence of acute kidney injury and impact on the patient outcomes with COVID-19

remains unclear but is of particular interest given the need to plan for deploying limited renal replacement therapy options in an acute clinical setting and questions about prognosis. Reports from previous outbreaks of SARS and MERS-CoV described notable rates of acute renal failure, ranging from 5-15% of total cases and utilization of continuous renal replacement therapy (CRRT) for 5-58% of critically ill patients. 5, 6, 7, 8 The extent to which pre-existing chronic kidney disease (CKD), including end-stage kidney disease (ESKD), or the development of acute kidney injury (AKI), are associated with severe COVID-19 and inferior outcomes is not clear either given their association with relative immune dysregulation and exaggerated inflammatory responses. 9 Acute kidney injury can lead to impaired acid-base, fluid, and electrolyte homeostasis, all of which may contribute to worse outcomes for patients with COVID-19. Given the high prevalence of kidney disease in the United States, which currently has more cases of COVID-19 than any other nation, an improved understanding of the associated risks as well as the need for the resources and the impact on outcomes are needed to inform clinical management and resource planning during the pandemic. Given the relative paucity of reports focused on 5 kidney-related outcomes, in this systematic review we assess the incidence of AKI among patients with COVID-19 and examine their associations with patient outcomes as reported in the available literature thus far.

The review was conducted in accordance with the Preferred Reporting Items for Systematic

Reviews and Meta-Analyses (PRISMA) statement (Supplemental Figure 1 ). Literature for this review was identified by searching MEDLINE, SCOPUS, EMBASE, and medRxiv databases.

The following search terms were used: ("COVID" OR "SARS-COV-2") AND ("outcomes" OR "clinical features" OR "clinical characteristics") AND ("acute kidney injury" OR "acute renal injury" OR "acute kidney failure" OR "acute renal failure" OR "chronic kidney disease" OR "chronic renal disease" OR "chronic kidney insufficiency" OR "chronic renal insufficiency").

The search was limited to original research published between December 1, 2019 and May 24, 2020 with full text available in English.

Articles were initially screened by title and abstract to assess for relevance; those with specialized populations such as pediatric, pregnant, transplant, ESKD, or cancer patients were excluded, as were reviews, case reports, cross-sectional studies, and randomized controlled trials for drug therapies. The full texts of the remaining studies were then assessed for the following inclusion criteria: retrospective and prospective cohort studies and case series with more than 20 patients, with extractable quantitative data on patient demographics, as well as data on acute kidney injury (AKI), chronic kidney disease (CKD), interventions used, and outcomes. We stringently excluded all studies that did not specify use of the Kidney Disease Improving Global Outcomes (KDIGO) criteria to define AKI. 10 When multiple studies were published from the same institution with data from similar time periods with likely overlapping cohorts, we selected one study for inclusion in the meta-analysis, based on the following criteria in order of priority:

the most general population, most detailed extractable kidney-related data, and largest number of patients included. Two authors independently screened all retrieved studies and assessed full text articles for inclusion; disagreements were resolved through consensus. Neither reviewer was blind to journal titles, study authors, or institutions.

Clinical information including cohort demographics and prevalence of comorbidities including CKD were extracted. Similarly, information on all kidney related complications and outcomes including incidence of AKI, need for renal replacement therapy (RRT), and mortality, were identified and extracted. The primary outcomes of interest were mortality and severe illness, Figure 3) .

Medians, interquartile ranges, and overall ranges were calculated for continuous demographic and clinical variables from all reported study-level values among the 20 studies meeting inclusion criteria. Random-effects meta-analyses were performed to obtain pooled prevalence, pooled odds ratio estimates, and 95% confidence intervals for categorical variables as well as for severe illness and mortality outcomes using the meta and metaprop commands. After the initial analysis, heterogeneity in mortality outcomes was investigated by excluding cohorts with particularly high mortality, as well as by conducting stratified analyses. We stratified studies based on pre-print versus peer-reviewed status, geographic location (Europe, Asia, or United States), and illness severity (<50% or ≥50% of the cohort severely ill). All analyses were performed using Stata 16 (College Station, TX), and an alpha of 0.05 determined statistical significance.

We screened a total of 512 articles, of which 59 full-text articles were assessed for eligibility and 30 met our inclusion criteria ( Figure 1 ). 3 included in the statistical analysis, 13 were from China, 1 was from Korea, 3 were from the U.S., and 3 were from Europe. The quality of peer-reviewed studies and pre-print studies were similar (Supplemental Table 1 ).

Across the 20 cohorts, the median age was 56 years (range 43 to 72 years) with 55% male patients (Table 1) . Forty-three percent (range 13.3-100%) of patients either required an ICU admission or were reported to have severe infection, and 11% (range 0-52.4%) of patients died.

Only 5% (range 0.6-57.1%) of all patients were reported to have evidence of CKD at baseline; however, one ICU cohort from the United States reported a CKD prevalence of 57.1%. 12 The prevalence of diabetes was 17% (range 6-33.3%) and the prevalence of hypertension was 33% (range 11.5-64.7%). Only one study, Pei et al, reported presence of proteinuria (43.9%) or hematuria (26.7%) on admission. 22 Four studies reported the prevalence of use of reninangiotensin-aldosterone-system (RAAS) inhibition prior to admission (24%, range 11.5-32%). 19, 22, 24, 26 The prevalence of AKI across the 20 cohorts was 17% with a range of 0.5 to 80.3% (Table 2) .

Six studies provided a breakdown of the severity of AKI using KDIGO staging (15% stage 1, 7% Nine studies provided enough details in their reported outcomes to determine the association of AKI with subsequent mortality (Figure 2 Figure 4) . Figure 5 shows a funnel plot including all 9 studies used to calculate the OR of death among patients with AKI. Further investigation is needed to elucidate the risk conferred by AKI among patients with specific comorbidities of interest, such as diabetes or hypertension. Among the cohorts we identified, such data was extremely limited. Data for proteinuria, hematuria, or home use of RAAS inhibitors were also extremely limited, despite current clinical interest and their potential to affect clinical outcomes. In addition, we were only able to study the association between renal disease and severe illness or death; other pertinent clinical questions including the apparent temporal association of AKI with intubation or the association of AKI with time to extubation, hospitalization time, and overall disease-related morbidity could not be examined using the currently available data. Absent data about renal recovery from the cohorts prevented any estimation of the extent of renal recovery among patients who survived to discharge.

Our study has several limitations. While our inclusion criteria requiring explicit adherence to the KDIGO definition of AKI enabled us to compute meaningful analyses across cohorts, this also resulted in excluding studies that did not specify using the KDIGO definition from our final analysis. In addition, given the rapid continuous expansion of the COVID-19 literature, many cohorts had relatively short follow up periods and limitations in their description of details, and there are new cohorts being reported continuously. Furthermore, as with any review, despite a detailed, comprehensive search strategy by 2 independent reviewers, it remains possible that some studies were missed. Finally, we allowed non-peer-reviewed literature to be more inclusive. However, the lack of peer review of these analyses may adversely impact the stability of our estimates. Nevertheless, analysis based on the NHLBI Study Quality Assessment Tool showed similar quality among the pre-print and peer-reviewed studies, and heterogeneity among the 4 pre-print studies used for meta-analysis was actually lower than that of the peer-reviewed studies.

In conclusion, there is a growing body of evidence that AKI occurs in a substantial number of COVID-19 cases, and that developing AKI is associated with significantly worse outcomes for patients with COVID-19. Given the extent of the adverse impact of AKI, it is imperative that future studies provide more detailed information the extent and severity of the renal injury as well as the need for RRT to allow for a more nuanced understanding of the prognosis for patients with COVID-19 and appropriate resource planning in this pandemic.

All the authors declared no competing interests 

A distinct name is needed for the new coronavirus

Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study

Clinical features of patients infected with 2019 novel coronavirus in Wuhan

Clinical Characteristics of Coronavirus Disease 2019 in China

Critically Ill Patients With the Middle East Respiratory Syndrome: A Multicenter Retrospective Cohort Study

Acute renal impairment in coronavirus-associated severe acute respiratory syndrome

A major outbreak of severe acute respiratory syndrome in Hong Kong

The Novel Coronavirus 2019 epidemic and kidneys

The immune system and kidney disease: basic concepts and clinical implications

KDIGO clinical practice guidelines for acute kidney injury

Diagnosis and Treatment Protocol for Novel Coronavirus Pneumonia

Characteristics and Outcomes of 21 Critically Ill Patients With COVID-19 in Washington State

COVID-19: a retrospective cohort study with focus on the over-80s and hospital-onset disease. medRxiv

COVID-19 in a designated infectious diseases hospital outside Hubei Province

Acute Kidney Injury in Hospitalized Patients with COVID-19. medRxiv

Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study

Clinical and immunological features of severe and moderate coronavirus disease 2019

Kidney impairment is associated with in-hospital death of COVID-19 patients

PATIENTS HOSPITALIZED WITH COVID-19. Kidney Int

Clinical Features and Outcomes of 98 Patients Hospitalized with SARS-CoV-2 Infection in Daegu, South Korea: A Brief Descriptive Study

Clinical features and management of severe COVID-19: A retrospective study in Wuxi

Renal Involvement and Early Prognosis in Patients with COVID-19 Pneumonia

Transmission and clinical characteristics of coronavirus disease 2019 in 104 outside-Wuhan patients

Epidemiology, risk factors and clinical course of SARS-CoV-2 infected patients in a Swiss university hospital: an observational retrospective study. medRxiv

Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the

Characterisation of Acute Kidney Injury in Critically Ill Patients with Severe Coronavirus Disease-2019 (COVID-19)

Association of Cardiac Injury With Mortality in Hospitalized Patients With COVID-19 in Wuhan, China

Clinical characteristics of 101 COVID-19 nonsurvivors in Wuhan, China: a retrospective study

Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China

Clinical course and outcome of 107 patients infected with the novel coronavirus, SARS-CoV-2, discharged from two hospitals in Wuhan

Duplicate cohorts excluded for quantitative meta-analysis (n=10)